Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
515 Views
Recent Developments Not Encouraging
This Insight provides an update on developments in the US market related to biosimilars, and are of great significance to Celltrion Inc (068270...
151 Views
Cybercriminals and Activists Scale up Their Attacks – Who's at Risk and Why?
Distributed denial of service (DDoS) attacks have significantly increased in size, carried out by threat actors exploiting internet of things (IoT)...
304 Views
Quizartinib: FMS–like Tyrosine Kinase 3 (FLT 3) Inhibitor
Acute Myeloid Leukemia (AML) represents one of the largest hematologic cancer populations with one of the worst survival rates. Patients with r/r...
171 Views
Celltrion Healthcare IPO - Early Review on Key Issues
Celltrion Healthcare, which is Celltrion (068270)’s overseas sales and marketing unit, submitted the application for preliminary screening for...
255 Views